145 related articles for article (PubMed ID: 28006767)
1. A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.
Brynes RK; Wong RS; Thein MM; Bakshi KK; Burgess P; Theodore D; Orazi A
Acta Haematol; 2017; 137(2):66-72. PubMed ID: 28006767
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Brynes RK; Orazi A; Theodore D; Burgess P; Bailey CK; Thein MM; Bakshi KK
Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
[TBL] [Abstract][Full Text] [Related]
3. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
5. Fibrosis identified in the bone marrow biopsies of patients with essential thrombocythemia: its incidence and significance for the differential diagnostic considerations.
Marcinek J; Plank L; Szépe P; Balhárek T
Cesk Patol; 2008 Jul; 44(3):62-6. PubMed ID: 18783136
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nationwide study.
Ettrup MS; Jensen AØ; Engebjerg MC; Farkas DK; Nørgaard M; Cha S; Zhao S; Johansen P; Sørensen HT
Am J Hematol; 2010 Dec; 85(12):930-4. PubMed ID: 20981681
[TBL] [Abstract][Full Text] [Related]
7. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
[TBL] [Abstract][Full Text] [Related]
8. Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study.
Uto Y; Fujiwara S; Arai N; Kawaguchi Y; Kabasawa N; Tsukamoto H; Ariizumi H; Hattori N; Saito B; Yanagisawa K; Harada H; Mori H; Shiozawa E; Nakamaki T
Rinsho Byori; 2015 May; 63(5):548-56. PubMed ID: 26524893
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
Kuter DJ; Mufti GJ; Bain BJ; Hasserjian RP; Davis W; Rutstein M
Blood; 2009 Oct; 114(18):3748-56. PubMed ID: 19671919
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Scully M; Kaczmarski R; Myers B; Collins R; Emohare O; Bolton-Maggs PH
Br J Haematol; 2012 Apr; 157(2):259-60. PubMed ID: 22091659
[No Abstract] [Full Text] [Related]
11. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
12. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
13. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
Vlachaki E; Sousos N; Perifanis V; Kaiafa G; Onoufriadis I; Hatzitolios A; Boura P
Acta Haematol; 2015; 133(1):78-82. PubMed ID: 25170628
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
18. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
19. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Bussel JB; Saleh MN; Vasey SY; Mayer B; Arning M; Stone NL
Br J Haematol; 2013 Feb; 160(4):538-46. PubMed ID: 23278590
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]